Oncolytics Biotech Inc T.ONC

Biotech Take Over - Wall Street Journal

[SundayMovies]

https://www.wsj.com/articles/the-biotech-takeout-menu-gets-pricier-11670477036

[Noteable]

December 20, 2022 -  Biotech stocks don’t behave like havens in a volatile market. Many have been trading below the value of their cash reserves over the past year. But a subset of the sector, those best positioned to help fill big pharma’s looming sales holes, are outperforming their peers. Large-cap biopharma companies are facing a $200 billion patent cliff, with sales of

[fox7mf]

With all that ONC brings to the table for a potential acquirer, I could see a valuation for this biotech being in a similar neighborhood to Abiomed. My opinion. Good luck longs.

[Noteable]

Although Abiomed is a medical device company its current market cap is US$17 Billion. A market cap of US$17 Billion is significant for a medical device company in the auxilliary heart pump device business when the global heart pump device market size is estimated to be USD$ 5.5 billion by 2026. Up from US$1.6 Billion in 2020. https://www.marketsandmarkets.com/Market-Reports/heart-pump-device

[Noteable]

As background ... the global immune checkpoint inhibitors market size was reported to be US$ 31.4 billion in 2021 and it is expected to hit around US$ 148.1 billion by 2030. [  Immune Checkpoint Inhibitors are around 15% effective. The intent of having ONCY's pelareorep added to immune checkpoint inhibitors is to increase the effectiveness of both checkpoint

[Noteable]

Abiomed receives FDA accelerated approval for heart pump device. Today Abiomed announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Abiomed has a market cap of US$17.1 Billion https://www.biospace.com/article/releases/fda-approves

[Noteable]

December 21, 2022 Repost : Abiomed receives FDA accelerated approval for heart pump device. Today Abiomed announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Abiomed has a market cap of US$17.1 Billion https://www.biospace.com/article

[TitanBrawler]

Notable, is Matt paying you in ONC shares.  Cause I just noticed Matt sold a little more then 14,000 shares. Lol. 

[Noteable]

TitanBrawler - you and Quentin30's posts are totally irrelvant since you don't hold any shares in ONCY. G'day mate.

[Noteable]

Furthermore the likes of TitanBrawler can't even understand SEC Insider filings since Matt Coffey didn't sell stock. In fact 14K of Matt Coffey's stock options expired on December 19th. So once again, as stupid as he is, TitanBrawler has once agin tried to distort the facts to suit his hedge fund & MM masters OR he really is that STUPID. Filing Date

[TitanBrawler]

Lol..  Expired.  Think about it dumbbell  Lmao. 

[Noteable]

Yeah I thought about it TitanBrawler and I come up with the same hedge fund/MM pimp title for you. The kind that holds no shares in this stock but keeps "slapping" his wang to get his rocks off on this message board.

[Noteable]

TitanBrawler is one of TD/National Bank Financial pimps on the TSX.

[TitanBrawler]

Damn I love Jousting with you . It's gonna be Easy pickings . And Gonna double money again. Keep up the good work . You'll earn that gold star from me very soon..

[Noteable]

This post has been removed in accordance with Community Policy